SHIELD THERAPEUTICS PLC Logo

SHIELD THERAPEUTICS PLC

Commercializing a novel oral therapy for adults with iron deficiency.

STX | IL

Overview

Corporate Details

ISIN(s):
GB00BYV81293
LEI:
213800G74QWY15FC3W71
Country:
United Kingdom
Address:
NORTHERN DESIGN CENTRE STUDIO 6, 3RD FLOOR, NE8 3DF GATESHEAD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company focused on addressing the significant unmet medical need for patients with iron deficiency. The company's lead product is ACCRUFeR® (ferric maltol), a novel, stable, non-salt-based oral therapy for adults suffering from iron deficiency, with or without anemia. Shield Therapeutics is dedicated to the commercialization of its innovative treatments to improve the lives of patients across multiple therapeutic categories.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-01 09:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 13.5 KB
2025-10-01 08:02
Regulatory News Service
Positive efficacy and tolerance in pediatric trial
English 18.7 KB
2025-09-15 08:00
Share Issue/Capital Change
£1.5 million placing supporting growth of ACCRUFeR
English 18.2 KB
2025-08-27 08:13
Regulatory News Service
Data published -European Journal of Heart Failure
English 21.9 KB
2025-08-21 13:06
Earnings Release
Interim results for the six months ended 30 Jun 25
English 245.5 KB
2025-05-22 11:40
Annual Report
Shield Therapeutics plc 2024 Annual Report and Accounts
English 4.4 MB
2025-04-22 08:01
Business and Financial Review
Licence Agreement in Japan for ACCRUFeR®
English 22.9 KB
2025-03-11 08:00
Regulatory News Service
ACCRUFeR® launched in Canada
English 21.0 KB
2025-02-13 17:15
Director's Dealing
PDMR Transaction Notification
English 28.6 KB
2025-02-13 08:00
Remuneration Information
Grant of Share Options
English 28.1 KB
2025-02-05 08:00
Earnings Release
Unaudited full year trading update
English 22.4 KB
2025-01-27 08:00
Board/Management Information
Anders Lundstrom appointed CEO
English 18.7 KB
2024-12-24 12:25
Post-Annual General Meeting Information
Result of General Meeting & Total Voting Rights
English 27.9 KB
2024-12-23 08:00
Share Issue/Capital Change
Results of RetailBook Offer
English 20.0 KB
2024-12-06 12:31
Share Issue/Capital Change
RetailBook Offer
English 31.8 KB

Automate Your Workflow. Get a real-time feed of all SHIELD THERAPEUTICS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SHIELD THERAPEUTICS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.